Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-11-10

FDA Approved: CHILDRENS XYZAL ALLERGY — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for CHILDRENS XYZAL ALLERGY (levocetirizine dihydrochloride) from Chattem, Inc., expanding the labeling for pediatri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CHILDRENS XYZAL ALLERGY (LEVOCETIRIZINE DIHYDROCHLORIDE)

Snippet

SUPPL AP for CHILDRENS XYZAL ALLERGY (LEVOCETIRIZINE DIHYDROCHLORIDE)